<DOC>
	<DOCNO>NCT03098199</DOCNO>
	<brief_summary>This research study hormone woman call anti-mullerian hormone ( AMH ) indicator amount egg reserve ovary . The research involve blood draw determine AMH level . This knowledge help investigator decide dosage gonadotropin , hormone use stimulate production one egg use vitro fertilization ( IVF ) cycle . The amount gonadotropin give tailor individual participant . The investigator use information participant hormone level determine dosage chance become pregnant result IVF treatment . The reason investigator research find base gonadotropin dosage solely participant 's AMH level give investigator well result previous method base age hormone level .</brief_summary>
	<brief_title>AMH Dosing Regimens Initial IVF Stimulation Protocols</brief_title>
	<detailed_description>Background / Rationale Anti-Müllerian Hormone ( AMH ) establish valuable biomarker ovarian reserve . It glycoprotein produce granulosa cell ovary ; regulate development primary follicle inhibit recruitment surround follicle . Day 3 FSH basal antral follicle count traditionally use assess ovarian reserve remain excellent predictor poor ovarian response , show predict IVF success rate . Given association AMH ovarian reserve , propose AMH level use predict ovarian response gonadotropin stimulation also , IVF success rate . An inverse relationship AMH total gonadotropin dosage previously demonstrate . As , concept tailor stimulation protocol patient 's potential oocyte production base AMH level gain favor . Individualization allow practitioner use minimum dosage medication require maximum response , limit risk ovarian hyperstimulation syndrome . The question become determine dosage medication require AMH level effect clinical outcome ? Hypothesis 1 ) Knowledge AMH level use determine medication dosage start stimulation cycle result high oocyte yield time retrieval , high clinical pregnancy rate , high live birth rate . 2 ) Knowledge AMH level use determine initial medication dosage start stimulation cycle result few number dosage change mid-cycle . 3 ) Knowledge AMH level prior start stimulation cycle result use different initial stimulation dose compare cycle AMH unknown . 4 ) Knowledge AMH level use determine medication dosage prior start stimulation cycle result lower rate ovarian hyperstimulation syndrome ( OHSS ) . ( Defined &gt; =20 oocytes/follicles ) 5 ) Knowledge AMH level use determine medication dosage prior start stimulation cycle result lower rate cancel cycle . Methods Procedures . The AMH level patient assess initial fertility evaluation patient . Patients undergo control ovarian hyperstimulation ( COH ) GnRH antagonist protocol . They begin COH day 3 menstrual cycle may need begin approximately one week oral contraceptive . After one week , patient stop take oral contraceptive ovary appear quiescent transvaginal ultrasound serum E2 level low . These patient begin COH three day later . Gonadotropin dosage determine start cycle AMH level . Dosages adjust , begin third day gonadotropin , base clinical response , determine serum hormone level transvaginal ultrasound ovary throughout cycle . The patient begin take GnRH antagonist , Ganirelix Cetrotide , lead follicle measure ≥14mm transvaginal ultrasound . Patients trigger Lupron , hCG , lead follicle measure ≥20mm transvaginal ultrasound . All medication administer via subcutaneous injection . Transvaginal ultrasound-guided oocyte retrieval perform 36 hour trigger medication ( ) administer . Cycles poor ovarian response , define &lt; 3 follicle and/or peak estradiol level &lt; 600 pg/mL , cancel . Patients undergo culture day 5 embryo transfer ; number embryo transfer accord ASRM guideline . If patient exhibit symptom OHSS , discontinue luteal phase support embryo transfer , good quality blastocyst mbryos cryopreserved . All patient eligible embryo transfer continue luteal phase support protocol serum hCG pregnancy test 14 day post-retrieval . If serum hCG &lt; 5 mIU/mL , luteal phase support discontinue . If serum hCG ≥5 mIU/mL , Estrace continue take 8 week gestation Endometrin intramuscular progesterone oil continue use 10 week gestation . At point , patient release care obstetrician . The patient obstetrician contact pregnancy outcome data .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<criteria>first cycle IVF transfer fresh embryo use nonautologous oocyte ; prior diagnosis premature ovarian failure diminish ovarian reserve ; BMI &gt; = 40 ; cryopreservation cycle ; smoker ; use PGS/PGD ; use surgically retrieved sperm patient severe male factor ; oocyte embryobanking cycle</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antimullerian Hormone</keyword>
	<keyword>In vitro fertilization</keyword>
	<keyword>Medications</keyword>
	<keyword>Dosing</keyword>
</DOC>